Arcus Biosciences Inc. RCUS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small …
SectorHealthcare
ExchangeNYSE
IndustryBiotechnology
CountryUnited States
Employees601
TickerRCUS
Statistics
Market Cap$3.04B
Revenue (TTM)$247.0M
Net Income-$353.0M
Net Margin-142.9%
EPS$-3.29
P/E-7.23
P/S12.42
P/B5.58
EV/EBITDA-5.33
ROE-70.0%
Dividend Yield—
Price$24.19
Data: Twelve Data · Revenue = mcap / P/S